BG
KURA icon

Bellevue Group’s Kura Oncology KURA Stock Holding History

Bellevue Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,600
Closed -$118K – 158
2024
Q4 		$118K Hold
13,600
– – ﹤0.01% 151
2024
Q3 		$266K Buy
13,600
+3,600
+36% +$72.9K ﹤0.01% 140
2024
Q2 		$206K Buy
+10,000
New +$206K ﹤0.01% 145
2022
Q3 		– Sell
-63,700
Closed -$1.17M – 180
2022
Q2 		$1.17M Sell
63,700
-2,280
-3% -$32.8K 0.02% 136
2022
Q1 		$1.06M Buy
+65,980
New +$953K 0.01% 149
2021
Q4 		– Sell
-57,500
Closed -$1.08M – 209
2021
Q3 		$1.08M Sell
57,500
-500
-0.9% -$9.42K 0.01% 156
2021
Q2 		$1.21M Hold
58,000
– – 0.01% 148
2021
Q1 		$1.64M Hold
58,000
– – 0.02% 148
2020
Q4 		$1.89M Buy
58,000
+10,000
+21% +$351K 0.02% 146
2020
Q3 		$1.47M Buy
+48,000
New +$1.06M 0.02% 149
2020
Q2 		– Sell
-57,100
Closed -$568K – 215
2020
Q1 		$568K Sell
57,100
-100,700
-64% -$1.15M 0.01% 154
2019
Q4 		$2.17M Sell
157,800
-8,500
-5% -$126K 0.03% 128
2019
Q3 		$2.52M Buy
166,300
+21,100
+15% +$376K 0.05% 125
2019
Q2 		$2.86M Buy
145,200
+115,900
+396% +$1.92M 0.05% 120
2019
Q1 		$486K Buy
+29,300
New +$451K 0.03% 133

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group's KURA Position: Q1 2025 in Review

Bellevue Group sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 13,600 shares — an estimated $118K sold.

Bellevue Group first reported a position in KURA in Q1 2019 and held it in 15 quarters. The position peaked at $2.86M in Q2 2019. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Bellevue Group reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 13,600 Kura Oncology shares in Q1 2025, an estimated $118K.
  • Bellevue Group first reported a position in Kura Oncology in Q1 2019 and held it in 15 quarters.
  • Bellevue Group's Kura Oncology position peaked at $2.86M in Q2 2019.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.